×
Social Commerce Partners reported net income of roughly $802,992 for Q3 2026, the quarter ended September 30, 2026, up from about $727,000 in the prior quarter. The company posted no operating revenue , consistent with its position as a pre-business-combination SPAC (special purpose acquisition company).
RDAC shares rose roughly 107% over the past 30 days, climbing from about $5.44 to $11.27, after the company mutually terminated its merger agreement with HZJL Cayman Limited. The termination, effective October 30, 2026 and announced November 3, removed a key overhang that had left the stock trading at a steep discount to its trust-account value.
The $10.50 central target is not an analyst price target; it reflects the roughly $10.56 per-share cash held in RDAC's trust account, a redemption and liquidation reference point disclosed in its filings. With shares recently trading near $5.10, reaching $10.50 would require roughly 106% upside — a very large move.
Rising Dragon Acquisition (RDAC) climbed roughly 107% over the last 30 days, from about $5.44 to about $11.28, driven primarily by the mutual termination of its merger agreement with HZJL Cayman Limited. On November 3, 2026, shares jumped more than 100% in a single session after the two companies announced the deal was being scrapped, with no termination fee owed by either party.
RDAC (ordinary shares) and RDACU (units) are two listed securities of the same blank-check issuer, Rising Dragon Acquisition Corp., differing mainly in structure and liquidity. A mutual termination of the pending HZJL merger in late October 2026 reset the company's business-combination timeline and drove sharply elevated volatility in RDAC .
The central $10 target is not an analyst-derived figure. It reflects the approximate trust and redemption value per share in RDAC's trust account — a widely used reference point for SPAC shares. With a recent verified close of $5.10, reaching $10 would require roughly a 96% advance, a very large move in percentage terms.
Ribbon Acquisition Corp. (RIBB) shares declined roughly 11.9% over the trailing 30 days, slipping from a closing price of $7.96 to approximately $7.01. The move extends a broader drawdown: shares traded near $10.87 in early August, marking a decline of roughly 35% over the trailing quarter.
Goodvision AI Holding (ALIS) shares fell roughly 17% over the last 30 days, declining from a closing price of about $10.33 to around $8.55. The decline followed a burst of post-merger volatility tied to the company's completed business combination with Goodvision AI Inc. and its October 2026 name change from Calisa Acquisition Corp.
LUMA dropped -9.25%, falling from a $21.40 prior close to $19.42 during regular trading hours. The fund, which tracks photonics and optical-chip names, was dragged down by a broad sector sell-off, led by top holding Lumentum slumping roughly 10% as Marvell merger speculation cooled and investors locked in profits after a steep run-up.
The KraneShares Photonic and Optical ETF (LUMA) declined roughly 23.9% over the last 30 days, from a closing price of $25.50 on September 30, 2026, to about $19.42. The drop reflects a broad October pullback across photonics, optical-component, and optical-AI infrastructure names, which make up the fund's core exposure.
Churchill Capital Corp XI (CCXI) fell roughly 26% over the last 30 days, declining from a closing price of $11.62 on September 30 to an intraday level around $8.63. The stock is trading below its $10.00 initial public offering reference price, reflecting weak sentiment in the blank-check/SPAC segment.
FVN rose +8.16% to $12.06 during regular market hours, up from the prior session's $11.15 close. The advance extends a volatile stretch for this low-float, Shanghai-based SPAC, which recently resumed trading after a volatility pause.
ALISU, the Nasdaq-listed units of Calisa Acquisition Corp — recently renamed Goodvision AI Holding Limited — has declined roughly 18% over the last 30 days, from $11.60 to about $9.50. The move coincided with the final stages and completion of the company's business combination with AI inference infrastructure developer GoodVision AI.
The central target of $12 represents roughly a 10.5% upside from the latest verified price near $10.86, described as a modest move. This target is not an analyst consensus. IBAC has no credible, numeric analyst price targets, so the figure comes from public-discussion and valuation context rather than sell-side research.
IB Acquisition Corp. (IBAC) is a Nasdaq-listed special purpose acquisition company (SPAC) pursuing a business combination with GNQ Insilico Inc., a Canadian TechBio company integrating AI, quantum computing, and genomics for drug discovery. IBAC shares have traded in a narrow band anchored near the SPAC's net-asset value, with the latest close near $10.93 versus roughly $11.30 about 30 days earlier, a decline of roughly 3%.
Different business models: CCXI is Churchill Capital Corp XI, a special purpose acquisition company (SPAC) pursuing a merger with Agility Robotics, while SPRO is Spero Therapeutics, a clinical-stage biopharmaceutical company. Distinct risk profiles: CCXI's value hinges on completing its business combination, whereas SPRO's outlook depends on drug approvals, royalty income, and clinical pipeline progress.
MACI is down -15.36% in regular trading to about $8.65, versus Monday's $10.22 close, extending a sharp unwind. The move follows the October 22 shareholder approval of its merger with Italian e-grocery platform Everli, which briefly sent shares soaring after hours.
RFAI fell -9.85% to $32.29 during regular market hours, retreating from Monday's close of $35.82. The pullback follows the prior session's sharp speculative surge of roughly +25% to +37% tied to its pending $1.5 billion merger with Singapore-based AI drug-discovery firm Nanyang Biologics.
CRWV and NBIS are operating "neocloud" AI-infrastructure providers, while IACQ is a pre-revenue blank-check company, making its risk profile fundamentally different. CRWV has scaled revenue fastest (about $7.6 billion trailing twelve months) but remains unprofitable and highly leveraged, with shares trading near 52-week lows.
BKHA fell -12.65% during regular trading to roughly $4.28, giving back most of the prior session's +18.36% rally. The move reflects SPAC de-SPAC uncertainty: redemptions of ~$25.15 million announced Oct. 14 left only about $420,000 in trust, pressuring the pending Vesicor Therapeutics combination near its Oct. 22 deadline.